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ABSTRACT 
 
While recent studies have focused on methylene blue’s interaction with amyloid plaques and 
neurofibrillary tangles in Alzheimer’s disease,!no studies have investigated the efficacy of 
methylene blue in animal-lesion models of regional pathology relevant to AD.  The goal of 
this dissertation was to examine the effects of methylene blue on spatial memory in aged 
Wistar rats with lesions to the anterior thalamic nuclei (ATN), part of an extended episodic 
memory system that shows early pathology in AD and diencephalic amnesia. First, 12 ATN 
rats were compared to 14 aged shams (18 to 22 months old) to assess spatial memory 
acquisition in a standard water maze task (10 days). Rats in each group then received 
intraperitoneal injections of methylene blue (1 mg/kg) or placebo 1 hour after each daily trial 
for 10 days in which acquisition of a new platform position was examined, followed by a 
probe trial 5 days later. Anterior thalamic lesions impaired initial acquisition of the reference 
memory task. In the subsequent acquisition and probe trial, methylene blue treatment vs. 
placebo improved spatial learning in ATN rats, but there was no effect in sham rats. These 
results provide the first evidence that methylene blue may prevent the learning impairments 
observed in rats with lesions to the anterior thalamus and supports methylene blue as a 
potential therapeutic intervention for older humans with memory disorders associated with 
injury to the ATN and the extended episodic memory system. 
 
 
 7 
1. INTRODUCTION 
 
1.1 General Introduction 
 
Recent research has demonstrated that methylene blue can enhance memory in both 
normal and impaired animals. Furthermore, there is evidence from human clinical trials that 
methylene blue may prevent the symptoms of Alzheimer’s disease, and these findings have 
been supported by animal literature that has revealed that methylene blue has a range of 
positive effects on Alzheimer’s pathology. However, there have been no studies that have 
examined the effects of methylene blue on animals that model the pathology of older humans 
who have episodic memory deficits. The purpose of the present study was to establish 
whether a short chronic administration of methylene blue could enhance spatial memory in  
older rats with brain lesions in a region that is believed to play a critical role in the severe 
memory deficits evident in people who suffer from Alzheimer’s disease and other memory 
disorders. 
 
1.2 Methylene Blue 
 
Methylene Blue (MB) is a phenothiazine that has been used in medicine for more than 
100 years in the treatment of various diseases such as malaria, schizophrenia, and 
methemoglobinemia (Atamna et al., 1996; Bodansky & Gutmann, 1947; Deutsch et al., 
1997). It is also a redox dye that has cationic and lipophilic properties that attract it to the 
mitochondrial membrane, and based on these qualities it is used as a selective supravital stain 
for neurons (Visarius et al., 1997). Its redox couple feature allows it to be an electron 
mediator between enzymes and substrates. Low dose methylene blue enters mitochondria, 
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where it diverts a portion of the electron flow to molecular oxygen (Hassen & Fridovich, 
1979). Additionally, MB acts as a potent antioxidant that competitively inhibits the reduction 
of molecular oxygen to superoxide by acting as an alternative electron acceptor (Riedel et al., 
2003). The molecular formula for MB is C16H18N3SCl (Fig. 1). 
 
The half-life of MB is 5-6.5 hours and research has demonstrated that it is able to 
cross the blood brain barrier when administered intraperitoneally to rats (Peter et al., 2000). 
While high doses of MB can have dangerous effects in humans (Martinez, Jr., et al., 1978), it 
has been demonstrated that therapeutic doses of MB have little to no side effects that could 
affect the behaviour or health of subjects. Animal studies have indicated that MB may have 
both anxiolytic and antidepressant effects. For example, Eroglu & Caglayan (1997) have 
reported that doses of 7.5 - 30mg/kg MB increased entries to the open arms of the elevated 
plus maze in mice and doses of 15 and 30mg/kg significantly decreased immobility time in 
the forced swim test. However, Bruchey & Gonzalez-Lima (2008) suggest that it is unlikely 
that these behavioural effects induced by MB influence performance on memory tasks. 
 
 
 
 Figure 1: The structural formula of methylene blue. 
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1.3 Methylene Blue and Memory Enhancement 
 
Recent research on MB’s neurobiological and behavioural actions suggests that MB 
has powerful metabolic enhancing effects that facilitate memory. The memory enhancing 
effects of MB were first reported by Martinez, Jr. et al. (1978), who discovered that low dose 
post-training administration of MB improved memory retention in an inhibitory avoidance 
task in rats. They showed that 1 mg/kg MB given immediately post-training improved 
memory retention tested one day later, whereas animals given a 50 mg/kg dose of MB 
showed impaired learning. These results suggested that low-dose MB administration could 
facilitate the memory consolidation occurring in the brain following a learning session and 
that higher doses had a negative impact on memory. 
 
These findings led Callaway and colleagues (2002) to propose that the effects of MB 
on memory retention demonstrated in the study by Martinez, Jr. et al. (1978) may have been 
due to MB increasing mitochondrial respiration during a critical period of memory 
consolidation. MB increases mitochondrial oxygen consumption by shuttling electrons to 
oxygen in the electron transport chain (Visarius, et al. 1997). Callaway et al. (2002) found 
that post-training administration of 1 mg/kg of MB reversed spatial memory deficits in a 
hole-board maze produced by impaired mitochondrial respiration in rats given sodium azide, 
an inhibitor of cytochrome c oxidase (CO). CO is the terminal enzyme in the mitochondrial 
electron transport chain and is responsible for the utilisation of oxygen for metabolic energy 
production in the brain (Wong-Riley, 1989). Impaired CO activity has been associated with 
memory deficits, and is linked to various neurodegenerative diseases, such as Alzheimer’s 
disease (Gonzalez-Lima, 1998). 
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 There is also evidence from animal research that during acquisition of spatial 
memory tasks there is an increase in CO activity in brain regions associated with spatial 
learning. For example, Mendez-Lopez and colleagues (2010) recently found that CO activity 
was highest in the dentate gyrus, medial prefrontal cotrex, and the mammilary region 
following spatial memory training in the water maze. Thus, Callaway and colleagues 
conducted a follow up study (2004) where they demonstrated that low dose MB enhanced 
brain CO levels, as tested in vitro in brain homogenates and in vivo 24 hours after 
administration to rats. Rats administered 1 mg/kg MB in this study also showed significantly 
improved memory retention in a baited hole-board task compared to those treated with saline. 
Together, these studies suggest that an increased oxidative metabolic capacity in the brain, as 
measured through increased CO activity, is the potential mechanism whereby MB improves 
memory retention. 
 
Further studies have investigated the effects of MB on more complex learning tasks. 
Gonzalez-Lima & Bruchey (2004) found that memory retention of extinction of Pavlovian 
fear conditioning was enhanced with post-extinction administration of MB. Moreover, this 
enhancement was related to an increase in CO activity in the prefrontal cortical regions, brain 
regions that are associated with mechanisms of extinction memory. This study was extended 
by Wrubel et al. (2007a) who found that MB administration improved retention of the 
extinction memory as demonstrated by significant decreases in fear renewal in an animal 
model for susceptibility to learned helplessness. Therefore, Wrubel and colleagues’ results 
suggest that low-dose MB administered in conjunction with exposure behavioural therapy in 
humans may be a useful therapeutic agent to facilitate retention of extinction of conditioned 
fear or other traumatic memories (Gonzalez-Lima & Bruchey, 2004). Other research has 
examined the effects of MB on discrimination learning tasks that require repeated days of 
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training. While previous studies using the hole-board maze focussed purely on MBs effect on 
spatial memory, Wrubel et al. (2007b) used a task where the goal was not simply to find 
where the baited holes were but also to discriminate “when” non-reward trials were given. 
This study therefore tested temporal memory as well as spatial memory. They found that, 
following three days of discrimination training, rats treated daily with post-training MB (1 
mg/kg) reliably discriminated rewarded and non-rewarded trials, and that no such 
discrimination effects were observed in controls. 
 
MB has a half-life of 5-6.5 hours (Peter et al., 2000). Therefore, Bruchey & Gonzalez-
Lima (2008) have suggested that it is unlikely that an increase in memory retention observed 
more than 24 hours after the last injection of MB will reflect a continued direct action of the 
drug. Rather, they propose that such changes to memory are probably due to secondary brain 
metabolic effects occurring at a critical time in memory consolidation. MB increases CO 
enzymatic activity in a use-dependent manner, with brain regions requiring highest metabolic 
demand during memory consolidation in a particular task showing the largest increases in CO 
activity (Gonzalez-Lima & Bruchey, 2004). Although MB administration leads to enzyme 
induction after a few hours, enhanced metabolic capacity in the brain is not evident untill the 
following day (Bruchey & Gonzalez-Lima, 2008). Thus, MB does not show memory 
enhancing effects instantly, and MB treated subjects tend to demonstrate day to day 
improvement in performance. This indicates that MB should show beneficial effects in 
acquisition when the learning task requires daily testing and drug administration is given on a 
daily basis. However, very few studies of this nature have been undertaken thus far. Based on 
previous studies (summarised in Table 1.) demonstrating the memory enhancing effects of 
MB, it appears to be a useful compound not only in models of metabolic impairment, but also 
in normal subjects. It is therefore a very promising drug for memory improvement and, if 
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Table 1. Summary of animal studies that examine the memory enhancing effects of methylene blue 
 
Year 
 
Study 
 
Impairment/ Species/ Treatment 
Protocol 
 
Behavioural Tasks 
 
Outcomes 
 
  1978 
 
Martinez Jr., Jensen, Vasquez, 
McGuiness, & McGaugh 
 
Non-impaired mice/ Single dose 
following training (Either 0.01, 0.1 or 
1 mg/kg) 
 
Inhibitory avoidance response task 
 
-Memory improvement following 
1 mg/kg dose 
 
  2002 
 
 
Callaway, Riha, Wrubel, 
McCollum, & Gonzalez-Lima 
 
Metabolically-impaired rats using 
sodium azide/ Single dose following 
training (1 mg/kg) 
 
Spatial reference memory task using 
baited holeboard maze 
 
-Memory Improvement, equal to 
non-impaired rats 
 
  2004 
 
Callaway, Riha, Bruchey, Munishi, 
& Gonzalez-Lima 
 
Non-impaired  rats/ 5 days repeat 
administration (1 mg/kg) 
 
Spatial reference memory task using 
baited holeboard maze 
 
-Memory Improvement 
-CO activity increased 
 
  2004 
 
Gonzalez-Lima & Bruchey 
 
Non-impaired  rats/ 5 days repeat 
administration (4 mg/kg) 
 
Fear acquisition/extinction memory 
task using tone-shock pairing 
 
-Improved retention of the 
extinction memory 
-CO activity increased 
 
  2005 
 
Riha, Bruchey, Echevarria, & 
Gonzalez-Lima 
 
Non-impaired/ rats/ Single dose 
following training (4 mg/kg) 
 
-Open field habituation 
-Object Recognition 
 
-Improved behavioural 
habituation 
-Improved recognition memory 
-CO activity increased 
   
  2007a 
 
Wrubel, Barret, Shumake, Johnson, 
& Gonzalez-Lima 
 
Congenitally helpless rats (learned 
helplessness model)/ 5 days repeat 
administration (4 mg/kg) 
 
Fear acquisition/extinction memory 
task using tone-shock pairing 
 
-Improved retention of the 
extinction memory 
 
  2007b 
 
Wrubel, Riha, Maldonado, 
McCollum, & Gonzalez-Lima 
 
Non-impaired rats/ 3 days repeat 
administration (1 mg/kg) 
 
Spatial discrimination memory task 
using baited holeboard maze 
 
-Memory Improvement 
-CO activity increased 
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administered correctly and in low doses, could provide a potent resource for those looking for 
memory enhancing compounds with little to no side effects for the treatment of 
neurodegenerative disorders.  
 
1.4 Methylene Blue and Alzheimer’s Disease 
 
 Recently, the potential of MB to slow down cognitive decline in Alzheimer’s disease 
(AD) has attracted attention. AD is the most common cause of dementia in the elderly 
affecting approximately 13% of adults over 65 in the United States (The Alzheimer’s 
Association, 2010). Clinically, it is characterised by progressively severe memory loss, 
neuropsychiatric disturbances, and eventual death (Barten & Albright, 2009). Histological 
hallmarks are extracellular deposits of β-amyloid protein in neuritic plaques, intracellular 
neurofibrillary tangles caused by the abnormal aggregation of tau protein, and neuronal cell 
loss, particularly affecting the cholinergic system. Recent studies have demonstrated that MB 
has action on many of the cellular and neurotransmitter pathologies observed in AD, and 
these findings highlight its potential as a therapeutic intervention not only for AD but for a 
range of human memory disorders. 
 
Strong evidence exists that the accumulation of the β-amyloid protein plays a major 
role in AD pathogenesis. β-amyloid protein aggregation, which leads to extracellular fibrillar 
deposits known as amyloid plaques, is a complex process involving either an increase in the 
protein’s production or a decrease in its degradation (Hardy & Selkoe, 2002). Although the 
mechanisms underlying the oligomerization and fibril formation of amyloid plaques is not 
clearly understood, it is pertinent that MB has been shown to inhibit β-amyloid 
oligomerization in vitro (Necula et al., 2007). In addition, MB administered to preformed β-
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amyloid have been expanded on in animal studies using transgenic mice. Medina et al. (2010) 
examined MB using the transgenic mouse model 3xTg-AD, which develops age-dependent 
accumulation of β-amyloid and tau. They observed that chronic dietary MB treatment 
reduced β-amyloid protein levels and improved the learning and memory impairments 
observed in this mouse model. This study concluded that the mechanisms underlying the 
effects of MB on β-amyloid pathology was mediated by an increase in proteasome function. 
The proteasome system is involved with the cleavage, and subsequent clearing, of β-amyloid, 
and decreased proteasome activity has been reported in human AD brains (Oddo, 2008). 
However, exactly how MB effects proteasome function is yet unknown and the authors have 
recommended that further research needs to be undertaken in order for the mechanisms by 
which MB increases proteasome activity to be better understood (Medina et al., 2010). 
 
Neurofibrillary tangles (NFTs) consist of paired helical filaments and straight 
filaments, which are made of the microtubule-associated protein tau in a hyperphosphorylated 
state (Iqbal & Novak, 2006). The accumulation of hyperphosphorylated tau protein correlates 
with neuronal loss and the severity of cognitive impairment in AD. In an early study by 
Wischik et al. (1996), a number of phenothiazines were investigated for their potential to 
inhibit aggregates of truncated tau protein. MB was among those phenothiazines that were 
found to be successful in this task through reversing the proteolytic stability of paired helical 
tau filaments. Similar results were observed in a more recent study, where it was found that 
MB inhibits heparin-induced assembly of tau protein into filaments in vitro (Taniguchi et al., 
2005). It is acknowleged that a four-repeat peptide in the microtubule-binding domain of tau 
protein plays an essential role in filament formation (Friedhoff et al., 2000), and therefore, the 
importance of this repeat domain in the inhibitory effects of MB on filament formation was 
also recently investigated in an in vitro study (Hattori et al., 2008). In this study, it was 
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demonstrated that the inhibitory responses with respect to heparin-induced filament formation 
to the second and third repeat peptides of the mictotubule-binding domain were not altered by 
MB. This suggests the importance of the first and fourth repeat peptides in the inhibitory 
activity of MB for tau filament formation. 
 
Given its tau-dissolving properties, the efficacy of MB as a therapeutic for AD has 
been tested using transgenic mouse models of human tau pathology. Harrington et al. (2008) 
examined the effects of MB on tau pathology using a transgenic mouse model that 
overexpressed the repeat domain of tau. Post-mortem examination showed that these mice 
presented with abundant tau pathology in the hippocampus and entorhinal cortex, while those 
transgenic mice treated with 2 weeks of oral MB showed a significant reduction in counts in 
tau positive neurons in these regions. In addition to these findings, a separately published 
study using the same sample showed that the transgenic mice treated with MB showed a 
reduction in spatial problem solving deficits in a water maze task (Melis et al., 2008). 
Nevertheless, these results have been challenged in more recent transgenic animal studies. A 
study by O’Leary et al. (2010) showed that while MB is capable of reducing tau formation 
and improving cognition at high doses (1 mM infused directly into the hippocampi), it did not 
affect pathology in mice with pre-existing tangle formation and neurodegeneration. Similarly, 
MB failed to inhibit abnormal tau phosphorylation and neuronal cell loss, and did not 
ameliorate a swimming defect in a zebrafish model of tauopathy (van Bebber, 2010). 
Therefore, these contrary studies suggest that MB may not reduce exisiting tau pathology, but 
may provide neuroprotection by reducing soluble tau levels. 
 
 Methylene blue has also been investigated in a phase 2 human clinical trial with a 
formulation called Rember™ (Wischik et al., 2008). An exploratory, placebo-controlled trial 
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conducted in 332 individuals diagnosed with mild to moderate AD found that after six 
months those receiving the compound experienced a significant improvement in cognitive 
function as compared to those receiving placebo. Over the course of a year, MB slowed the 
progression of AD by 81%, with SPECT- and PET-scan evidence showing increased glucose 
metabolism in brain regions affected by tau pathology (Murray et al., 2008). However, while 
these results appear promising, criticism has been raised concerning the clinical trial’s 
validity. The results have, up until now, been presented at a conference but have not yet been 
published in a peer-reviewed journal. In addition, the gelatine capsules containing the highest 
MB dose were reportedly defective, and the data of this dosage group was folded into the 
placebo group (Sullivan, 2008). Furthermore, issues with study blinding have been put 
forward as MB turns the subjects urine blue (Sullivan, 2008). There has been little 
information released on the progress of these human trials following 2008 and, consequently, 
further clinical studies are required to investigate the potential of MB as a therapeutic 
intervention for human AD. 
 
 While the majority of research investigating MB as a therapeutic for AD has focussed 
on its effects on tau and amyliod pathology, there is also evidence that the drug interacts with 
the cholinergic system, which is the target of current AD medications. The cholinergic 
system plays an important role in the regulation of learning and memory and studies have 
linked cholinergic dysfunction to aspects of the neuropathology and cognitive dysfunction in 
AD (Nordberg, 2006). The primary medications currently prescribed to AD patients are 
various acetylcholinesterase inhibitors (AChEIs), although treatment effects are often mild. It 
is generally recognised that these treatments offer only temporary symptomatic benefit and 
there is little evidence that they modify the course of the disease (van Dam et al., 2008). The 
cost-effectiveness of these AChEI medications have also been questioned (Kaduszkiewicz et 
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al., 2005). There is evidence that MB acts as a cholinesterase inhibitor (Pfaffendorf et al., 
1997), and thus currently prescribed AChEIs have been compared with MB using a 
pharmacological animal model of AD. In a study by Deiana and colleagues (2009), it was 
demonstrated that MB was superior to the commonly-used AChEI, rivastigmine, in reversing 
a spatial-learning impairment induced by anti-cholinergic scopolamine treatment. 
Furthermore, when combined with rivastigmine the effect of MB was potentiated, suggesting 
that some of the side effects associated with higher rivastigmine doses could be avoided by 
adding low doses of MB to lower doses of rivastigmine (Deiana et al., 2009). 
 
 Another medical benefit for using MB in the treatment of AD has been proposed 
through its neuroprotective effects via enhanced mitochondrial function and increased heme 
synthesis. As explained previously, MB improves neuronal metabolic energy production 
through increasing CO activity. Impaired CO activity is a recognised feature of AD 
(Gonzalez-Lima, 1998), with a decrease in CO activity leading to cytotoxicity, increased 
oxidant production, and decreased energy charge of the mitochondria (Barros et al., 2004). 
Mitochondrial dysfunction and oxidative stress are thought to be key abnormalities that lead 
to cellular senescence and aging (Atamna et al., 2008). MB may therefore be useful in 
delaying mitochondrial dysfunction with aging and the decrease in CO in AD. Furthermore, 
MB increases heme synthesis (Atamna et al., 2008). An increase in heme synthesis is 
necessary to support the assembly of CO, and also supports other metabolic functions 
involved in decreased oxidant production (Carr & Winge, 2003). 
 
Another proposed mechanism of action of MB that could contribute to its positive 
effects on neurodegenerative disorders involves its antioxidant properties. MB inhibits 
superoxide by accepting electrons from tissue oxidases (Kelner et al., 1988; Salaris et al., 
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1991). It is also an inhibitor of nitric oxide synthase (Mayer et al., 1993) which can form free 
radicals after reacting with superoxide. A recent study has examined the effects of MB as an 
antioxidant to protect against rotenone-induced neurodegeneration in an animal model of 
optic neuropathy (Zhang et al., 2006). Rotenone is a neurotoxin that induces severe 
neurodegeneration, and previous studies have shown that it is associated with motor function 
impairment in the rat when selectively infused into the striatum (Sindhu et al., 2006). 
Neurodegeneration in the retinal ganglion cell layer 24 hours after rotenone injection was 
completely prevented by the injection of methylene blue plus rotenone. The author proposed 
that MB administration enhanced oxygen consumption and acted as an antioxidant in this 
study, preventing oxidative damage and cell death. The neuroprotective effects of MB have 
also been examined using rats with neurotoxic lesions to the striatum using rotenone (Rojas et 
al., 2009). Rotenone induced large anatomical lesions resembling “metabolic strokes”, and 
the size of these lesions was greatly reduced in MB-treated rats. In addition, MB prevented 
the decrease in CO activity and the perilesional oxidative stress associated with rotenone 
infusion in the striatum. These findings support the notion that MB could be a valuable 
intervention against neural damage associated with neurodegenerative disorders. 
 
 Prior to the study by Rojas et al. (2009), there was no research that examined the 
effects of MB using animal lesion models that attempt to represent the regional pathology of 
AD and other amnestic disorders. However, a recent study by Riha et al. (2010) investigated 
the memory-enhancing properties of MB in rats that received an infusion of sodium azide, a 
CO inhibitor, directly into the retrosplenial cortex. Retrosplenial cortex hypometabolism is a 
common feature in neurodegenerative disorders and results in oxidative damage, 
neurodegeneration and memory deficits (Mosconi et al., 2006; Vann & Aggleton, 2002). Riha 
et al. (2010) found that while sodium azide infusions into the retrosplenial cortex induced 
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impairments in visuospatial memory in a holeboard food-search task, an intraperitoneal dose 
of 4 mg/ kg MB immediately following surgery prevented such impairments. Administration 
of MB to rats with the metabolic lesions also reduced the retrosplenial cortex lesion volume 
and partially restored CO activity in brain regions disrupted by the lesion, such as the 
thalamus and hippocampus. This study is relevant to mild cognitive impairment and AD as it 
is the first to demonstrate that systemic MB administration can prevent the hypometabolic 
damage and impaired behavioural effects induced by mitochondrial insult. These findings 
support further investigation of MB using animal lesion models of neurodegenerative 
disorders. 
 
As summarised in Table 2., the positive effects of MB on memory have been 
demonstrated in animals expressing both β-amyloid pathology (Medina et al., 2010) and tau 
pathology (Harrington et al., 2008; Melis et al., 2008), and also in rats with cholinergic 
dysfunction (Deiana et al., 2009). Other recent studies have shown that MB is affective in 
ameliorating memory impairment in animals with “metabolic” lesions to brain regions 
associated with memory. Considering that the most recent study by Riha et al. (2010) 
examined animals with lesions to the retrosplenial cortex, a region that plays an integral part 
in normal episodic memory (Aggleton, 2008). it is therefore important that research extends 
upon their findings by examining MBs effect on animals with lesions to other regions of the 
brain involved in learning and memory, and that are implicated in human memory disorders. 
The current study aimed to examine the effect of MB on spatial memory in rats with 
neurotoxic lesions to the anterior thalamus. Rats with lesions to the anterior thalamus make 
an ideal model for amnestic disorders as this region has been heavily implicated in memory 
and learning (Aggleton, 2008; Kopelman, 2002). The following is an introduction to the 
anterior thalamus and a review of animal experimental findings pertaining to anterior 
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thalamic involvement in memory functioning in order to demonstrate the rationale for using 
this lesion model to examine the memory enhancing effects of MB. 
 
1.5 The Anterior Thalamus and Diencephalic Amnesia 
 
The thalamus is a part of a group of brain structures that constitue a major part of the 
diencephalon. The thalamus consists of a large number of nuclei, including the Anterior 
Thalamic Nuclei (ATN) (Fig 2.). The importance of the ATN is that they form part of a 
circuit that includes the hippocampus, mammilary bodies and cingulate/retrosplenial cortices. 
It has been proposed that this circuit is primarily involved in episodic memory (Aggleton & 
Brown, 1999). The ATN receive bilateral input from the hippocampus either directly via the 
subicular complex through the fornix (Aggleton, 1986) or indirectly through the mammilary 
bodies and the mammilothalamic tract (Vann et al., 2007). The ATN also have reciprocal 
connections with the retrosplenial cortex. This cortical region provides a route for indirect 
projections from the  diencephalon to the temporal lobe (Amaral & Price, 1984). The ATN 
project directly back upon the hippocampal formation (De Vito, 1980). Aggleton and Brown 
(1999) suggest that within this “extended hippocampal system” the ATN play a major role in 
diencephalic amnesia and that they function in a reciprocal fashion with the hippocampus.  
 
                  
              Figure 2. Representation of the thalamus and its nuclei.
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Table 2. Summary of animal studies examining the effects of methylene blue in animal models of Alzheimer’s disease/ neurodegeneration 
 
Year 
 
Study 
 
Sample- Impairment/ Treatment 
Protocol 
 
Behavioural Tasks 
 
Outcomes 
 
2006 
 
Zhang, Rojas, & Gonzalez-Lima 
 
Rotenone-induced optic neuropathy in 
rats/ local microinjection of MB (70 
µg/kg) 
 
none 
 
Optic neurodegeneration 
prevented in a dose-dependent 
manner. 
 
2008 
 
Harrington, Rickard, Horsley, 
Harrington, Hindley, Riedel, 
Theuring, Seng, & Wischik/ Melis, 
Deiana, Zabke, Stamer, Harrington, 
Riedel, Theuring, Seng & Wischik 
 
Transgenic mice expressing tau-
pathology/ 14 days repeat oral 
administration (15 or 45 mg/kg) 
 
Spatial reference memory in the 
water maze 
 
-Reduction in tau pathology 
-Memory improvement 
 
2009 
 
Deiana, Harrington, Wischik, & 
Riedel 
 
 
Anti-cholinergic scopolamine-induced 
amnesia in mice/ Single dose of 0.15-4 
mg/kg MB in mono or in combination 
with rivastigmine 
 
Spatial reference memory in the 
water maze 
 
-Memory improvement in a dose 
dependent manner when MB 
administered alone. 
-Enhanced memory improvement 
when combined with 
rivastigmine 
 
2009 
 
Rojas, Simola, Kermath, Kane, 
Schaller, & Gonzalez-Lima 
 
Rotenone-induced striatal neuropathy 
in rats/ Local microinjection of MB 
(70 µg/kg) 
 
-Open field task 
-Dot removal test 
-Vibrissae-evoked forelimb placing 
 
-Reduction in lesion volume 
-Increased CO activity and 
functional connectivity of motor 
regions. 
-Prevention of sensorimotor 
dysfunction elicited by rotenone  
 
2010 
 
Medina, Caccamo, & Oddo 
 
Transgenic mice expressing tau and 
Aβ-pathology/ 16 weeks of repeat oral 
administration (25 mg/kg) 
 
Spatial reference memory in the 
water maze 
 
-Memory improvement 
-Reduction in Aβ-pathology 
-No  reduction in tau-pathology 
-No effect on CO activity 
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2010 
 
O’Leary, Li, Marinec, Blair, 
Congdon, Johnson, Jinwal, Koren, 
Jones, Kraft, Peters, Abisambra, 
Duff, Weeber, Gestwicki, & Dickey 
 
Transgenic mice expressing tau 
pathology/ Single administration of 
with 1mM or 0.1mM MB infused into 
the hippocampi. 
 
Spatial reference memory in the 
water maze 
 
- Memory improvement only 
after high dose. 
-No reduction in existing tau-
pathology. 
-Reduction in further tau 
formation after high dose. 
 
2010 
 
van Bebber, Paquet, Hruscha, 
Schmid, & Haass. 
 
Transgenic zebrafish expressing tau 
pathology/ Embryos were cultured in a 
solution containing either 10µM or 
100µM MB for up to 6 days. 
 
Escape response test 
 
-No reduction in tau pathology 
-No effect on dysfunctional 
swimming behaviour 
 
2010 
 
Riha, Rojas, & Gonzalez-Lima 
 
Sodium-azide induced retrosplenial 
cortex hypometabolism in rats/ Single 
dose (4 mg/kg) following surgery 
 
Spatial reference memory in the 
baited holeboard maze. 
 
-Memory improvement 
demonstrated in probe trial 
-Reduction in lesion volume 
-Increased CO activity in regions 
connected to the retrosplenial 
cortex 
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Until recently there has been a firmly held belief that the thalamus functions primarily 
as a relay station which transmits information from the limbic regions to the cortex (Jones, 
1985), and that memory deficits observed after thalamic lesions may arise from a 
disconnection to the information flow between the brain regions involved in memory (Macchi 
& Jones, 1997). However, more recent research suggests the anterior thalamus contributes to 
episodic memory operation and that its function is not just limited to passively processing 
hippocampal outputs (Aggleton, 2008). It is now almost universally agreed that the 
hippocampal formation is a crucial region implicated in anterograde amnesia (Squire et al., 
2004), a condition defined by the presence of a severe deficit for the recall of recent events  
that contrasts with intact short-term memory, semantic memory IQ, and skill learning (Parkin, 
1991). While early reports suggested that hippocampal damage and diencephalic damage 
might produce qualitatively different kinds of memory dysfunction (Huppert & Piercy, 1978), 
the current view is that damage to either region results in an amnesic syndrome that is 
characterised by a common impairment in anterograde and retrograde declarative memory 
but intact non-declarative memory (Gold & Squire, 2006). 
 
Diencephalic amnesia is most readily observed in cases of Korsakoff’s syndrome, a 
disorder arising from alcohol abuse and thiamine deficiency (Kopelman, 1995), as well as in 
other cases of thalamic damage produced by tumours, cysts and thalamic infarcts. Cases of 
Korsakoff’s syndrome in particular provide strong evidence of the contribution of the ATN to 
memory functioning. For example, a study by Harding et al. (2000) analysing the post-
mortem brain tissue of Korsakoff’s syndrome concluded that neuronal loss in the ATN was 
the most critical site for the presentation of amnesia, and not degeneration of the mammillary 
bodies or other thalamic regions. Alzheimer’s dementia affects most regions in the limbic 
system, including the ATN. It has been suggested that these changes in the ATN play a 
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critical part in the emergence of the severe memory problems associated with AD (Braak & 
Braak, 1991a; Johnson et al., 1998). Post-mortem examination reveals that both anterior 
thalamic and hippocampal changes occur relatively early in Alzhiemer’s pathology. Braak & 
Braak (1991a) suggest that these neuropathological thalamic changes may be responsible for 
hampering the transmission of information through limbic circuits and that this may lead to 
the cognitive deficits observed in the disease. Evidence from these neuropathological 
conditions highlights the role of the ATN in memory impairment. However, damage to the 
ATN in humans is often accompanied by damage to other thalamic nuclei, as well as white 
matter tracts that transverse the area, making direct relationships between structure and 
function hard to ascertain (Aggleton, 2008). Therefore, animal research using precise lesion 
placing is essential in clarifying the functional role of the ATN and has been used to create an 
animal model that replicates the cognitive impairments present in human memory disorders. 
 
1.6 Experimental Anterior Thalamic Lesions 
 
Permanent lesions to the ATN as well as lesions to the individual sub-nuclei in rats 
produce impairments in spatial memory as observed in behavioural tasks such as the water 
maze (Sutherland & Rodriguez, 1989; Van Groen et al., 2002; Wolff et al., 2008), radial 
maze (Mitchell & Dalrymple-Alford, 2006; Sziklas & Petrides, 2007), and T maze (Ward-
Robinson et al., 2002) (Table 3.). These deficits remain despite the rats being extensively pre-
trained before surgery, at least as observed in T-maze and standard water maze tasks 
(Warburton et al., 1999). There is little indication that ATN lesions impair memory of other 
classic non-spatial tasks, such as object recognition (Aggleton et al., 1995), sensory 
preconditioning (Ward-Robinson et al., 2002), configural learning (Moran & Dalrymple-
Alford, 2003) or egocentric (motoric) learning (Wolff et al., 2008). 
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The ATN consists of three subnuclei: anteroventral (AV); anteromedial (AM) and 
anterodorsal (AD). Questions have been raised as to whether damage to all or just some of 
the subcomponents is sufficient to produce the observed deficit in spatial memory. A study 
by Aggleton et al. (1996) has demonstrated that long-term persistent deficits on spatial 
memory tasks, such as a T-maze alternation task, are more likely to be obtained when 
damage to the whole complex is sustained, whereas AM only or AV plus AD lesions result 
only in delayed task acquisition. Van Groen et al. (2002) have also demonstrated that while 
selective damage to the anterior thalamus’ individual components produces impairments on 
working and reference memory tasks in the water maze, the animals were able to acquire the 
tasks over time. Total ATN damage, on the other hand, produced severe impairment with no 
improvements evident across trials. Such evidence strongly suggests that lesions involving all 
three anterior thalamic nuclei are required to produce severe longer-lasting deficits on tests of 
spatial memory processing. However, relatively minor non-specific damage to the ATN (i.e., 
when passing fibres are also affected) can produce severe deficits and may potentially 
contribute to the severity the observed diencephalic amnesia when the insult is sustained 
elsewhere (Byatt & Dalrymple-Alford, 1996). 
 
 From such studies as those summarised in Table 3, it has been acknowledged that the 
ATN is involved in spatial-working memory processing as well as the acquisition of spatial 
reference memory. This evidence highlights the functional similarity between the ATN and 
the hippocampus (Aggleton, 2008). Other evidence that supports the notion that the ATN and 
hippocampus are part of a functional system comes from studies that employ a cross-lesion 
method. In cross-lesion studies a unilateral lesion is placed in both structures of interest but in 
different cerebral hemispheres. The rationale behind such experiments is that unilateral
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Table 3. Summary of animal studies examining the effects of anterior thalamic lesions on memory. 
 
Year 
 
Study 
 
Lesion Method 
 
Behavioural Tasks 
 
Outcomes 
 
1989 
 
Sutherland & Rodriguez 
 
ATN/ Electrolytic/ Mice 
 
1. Working memory in the Water 
maze 
2. Reference memory in the Water 
maze 
 
1. Lesion= impaired 
2. Not impaired for same 
platform position, but impaired 
for position change. 
 
1989 
 
Beracochea, Jaffard & Jarrard 
 
ATN/ Ibotenic/ Rats 
 
1. 12-arm Radial maze 
2. Spatial reversal task 
 
1. Lesion = non-impaired 
2. Lesion = non-impaired 
 
1991 
 
Peinado-Manzano & Pozo-Garcia 
 
 
ATN/ Electrolytic/ Rats (Mediodorsal 
thalamus also damaged) 
 
Operant delayed alternation task 
 
Lesion = impaired 
 
1991 
 
Beracochea & Jaffard 
 
ATN/ Ibotenic & Alcohol/ Mice 
 
Spontaneous alternation task in T 
maze  
 
Lesion = impaired 
 
1991 
 
Aggleton, Keith & Sahgal 
 
ATN + Fornix/ NMDA/ Rats 
 
Operant delayed matching to postion 
 
Lesion = impaired 
 
1994 
 
Beracochea & Jaffard 
 
ATN/ Ibotenic/ Mice 
 
1. Delayed alternation task in T maze 
2. Sequential alternation task in T 
maze  
 
1. Lesion = impaired after long 
delay, but not after brief delay. 
2. Lesion = non impaired 
 
1996 
 
Byatt & Dalrymple-Alford 
 
Anterventral and Antermedial nuclei of 
ATN/ Radiofrequency/ Rats 
 
1. Working memory in 12-arm 
Radial maze 
2. Reference memory in 12-arm 
Radial maze 
 
1. Lesion = impaired 
2. Lesion = impaired 
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1996 
 
Aggleton, Hunt, Nagle & Neave 
 
ATN, Antermedial nucleus only, or 
Anterventral & Anterodorsal nuclei 
only/ NMDA/ Rats 
 
1. Forced alternation task in T maze 
2. Egocentric discrimination task 
3. Reference memory in 8-arm 
Radial Maze 
 
1. All lesions impaired, but full 
ATN lesions showing more 
impairment. 
2. All lesions non-impaired. 
3. Full ATN and 
Anteroventral/Anterodorsal 
lesions impaired, but 
Antermedial-only lesion non-
impaired. 
 
1999 
 
Warburton & Aggleton 
 
 
ATN or ATN+Fornix/ NMDA & 
Radiofrequency/ Rats 
 
1. Reference memory in Water maze 
+ Probe Trial. 
2. Forced alternation task in T maze 
3. Spontaneous object recognition 
task   
 
1. Both lesions impaired. 
2. Both lesions impaired, but 
ATN+Fornix worse. 
3. Both lesions non-impaired. 
 
1999 
 
Sziklas & Petrides 
 
ATN/ Electrolytic/ Rats 
 
1. Reference memory in 8-arm radial 
maze 
2. Spatial visual assocation task 
3. Visual egocentric task in T maze 
 
1. Lesion = impaired 
2. Lesion = impaired 
3. Lesion = non-impaired 
 
2000 
 
Warburton, Baird, Morgan, Muir & 
Aggleton 
 
ATN+Fornix Ipsilateral, ATN+Fornix 
Contralateral, or 
ATN+Fornix+Hippocampus 
Contralateral/ Cytotoxic/ Rats 
 
1. Spontaneous object recognition 
2. Object location in place task 
3. Forced alternation task in T maze 
4. Reference memory in Water maze 
5. Reference memory in 8-arm 
Radial maze 
6. Working memory in T maze 
 
1. All lesions non-impaired 
2. All lesions impaired 
3. All lesions impaired 
4. All lesions impaired 
5. All lesions impaired 
6. All lesions impaired 
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2002 
 
Ward-Robinson, Wilton, Muir, 
Honey, Vann & Aggleton 
 
ATN/ NMDA/ Rats 
 
1. Non-spatial sensory pre-
conditioning to fear 
2. Conditioned taste aversion 
3. Spatial forced Alternation task in 
T maze 
 
1. Lesion = non-impaired 
2. Lesion = non-impaired 
3. Lesion = impaired 
 
2002 
 
Van Groen, Kadish & Wyss 
 
Anterodorsal+Anteroventral nuclei, or 
Anterdorsal+Anteroventral+ 
Anteromedial nucei/ Ibotenic/ Rats 
 
1. Reference memory in Water maze 
 
1. All lesions = impaired 
 
2003 
 
Moran & Dalrymple-Alford 
 
ATN or Perirhinal cortex/ NMDA/ 
Rats 
 
1. Reference memory in 12-arm 
Radial maze 
2. Configural learning task 
3. Spontaneous object recognition 
task 
 
1. ATN lesion only = impaired 
2. Perirhinal cortex lesion only= 
impaired 
3. Both lesions = non-impaired 
 
2004 
 
Sziklas & Petrides 
 
ATN/ Electrolytic/ Rats 
 
1. Conditional associative learning 
task in the T maze 
 
1. Lesion = non-impaired 
 
2004 
 
Henry, Petrides, St-Laurent & 
Sziklas 
 
ATN unilateral + Hippocampus 
unilateral/ Electrolytic/ Rats 
 
1. Spatial conditional associative task 
2. Delayed forced alternation task in 
T maze 
 
1. Combined lesion = impaired 
2. Combined lesion = impaired 
 
2005 
 
Mitchell & Dalrymple-Alford 
 
ATN, Lateral Thalamus, or Medial 
Thalamus/ NMDA/ Rats 
 
1. Working memory in 8-arm Radial 
maze 
2. Reference Memory in 8-arm 
Radial maze 
3. Conditional associative learning 
task 
 
1. ATN & Lateral Thalamus = 
impaired; Medial Thalamus = 
non-impaired 
2. ATN & Lateral Thalamus = 
impaired; Medial Thalamus = 
non-impaired 
3. ATN & Lateral Thalamus = 
non- impaired; Medial Thlamus = 
impaired 
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2006 
 
Wolff, Gibb & Dalrymple-Alford 
 
ATN/ NMDA/ Rats 
 
1. Memory for temporal order of list 
of odours 
 
1. Lesion = impaired 
 
2006 
 
Mitchell & Dalrymple-Alford 
 
ATN or Lateral Thalamus/ NMDA/ 
Rats 
 
1. Working memory in the Plus maze 
2. Working memory in the 8-arm 
Radial maze 
 
1. Lateral thalamus only = 
impaired 
2. ATN only = impaired 
 
2006 
 
Gibb, Wolff, & Dalrymple-Alford 
 
ATN, Lateral Thalamus, or Medial 
Thalamus/ NMDA/ Rats 
 
1. Odour-place paired-association 
task 
2. Spatial and odour discrimination  
 
1. ATN and Lateral Thalamus = 
impaired; Medial Thalamus = 
non-impaired 
2. All lesions = non-impaired   
 
2007 
 
Sziklas & Petrides 
 
ATN/ Electrolytic/ Rats 
 
1. Visual-spatial conditional 
associative learning task 
2. Working memory in 8-arm Radial 
maze 
 
1. Lesion = non-impaired 
2. Lesion = impaired 
 
2007 
 
Loukavenko, Ottley, Moran, Wolff 
& Dalrymple-Alford 
 
ATN/ NMDA/ Rats 
 
1. Working memory in T maze 
 
1. ATN lesion = impaired, but 
non-impaired if housed in 
enriched environment at both 5 
and 40 days following surgery 
 
 
2008 
 
Wolf, Gibb, Cassel & Dalrymple-
Alford 
 
ATN or Intralaminar nulei of 
thalamus/ NMDA/ Rats 
 
1. Reference memory in the Water 
maze 
2. Left/Right discrimination in the Y 
maze 
 
1. ATN lesion only = impaired 
2. Both lesions = non-impaired 
 
2009 
 
Lopez, Wolff, Lecourtier, Cosquer, 
Bontempi, Dalrymple-Alford & 
Cassel 
 
ATN or Intralaminar nuclei+Lateral 
Thalamus/ NMDA/ Rats 
 
1. Reference memory in Water maze 
and delayed retesting 
 
1. ATN lesion= impaired across 
conditions; Intralaminar  
nuclei+Lateral Thalamic lesion = 
impaired only at retesting 
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2009 
 
Wolff, Loukavenko, Will, & 
Dalrymple-Alford 
 
ATN/ NMDA/ Rats 
 
1. Reference memory in Water maze 
2. Working memory in Water maze 
 
1. ATN lesion = impaired, but 
non-impaired if housed in 
enriched environment. 
2. ATN lesion = impaired, but 
non-impaired if housed in 
enriched environment. 
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 lesions in both structures in opposite hemispheres will only have a disruptive effect if 
the two regions form a part of a functional system, whereas unilateral lesions made in the 
same hemisphere will have relatively little effect on behaviour. Studies performed by 
Warburton and colleagues (2000; 2001) found that unilateral lesions to the ATN and opposite 
hemisphere unilateral lesions to the hippocampus or fornix produced impairments in spatial 
memory on T-maze, water maze and radial arm maze tasks. However, same hemisphere 
lesions only produced mild impairments in spatial memory. Warburton and colleagues 
suggested that this evidence provides direct support for the notion that the ATN and 
hippocampus operate in conjunction as part of an integrated neural network during learning. 
 
Declarative memory, as tested through associative learning tasks, is also affected by 
ATN lesions in rats. For example, ATN lesions result in severe deficits on spatial-visual tasks 
which require learning an association between scenes and objects embedded in them (Sziklas 
& Petrides, 1999), or between different odours and locations (Gibb et al., 2006). It has been 
demonstrated that the hippocampus also plays a role in the formation of associations between 
arbitrary visual stimuli and places or scenes (Sziklas et al., 1998). However, It should be 
noted that ATN deficits on associative learning are task dependent, and in some cases deficits 
are observed following hippocampal but not ATN lesions (e.g., Sziklas & Petrides, 2007). 
Further studies have shown that the functional connection between the ATN and hippocampal 
formation may rely on a direct route through the fornix, and indirectly between both the ATN 
and hippocampus through the retrosplenial cortex. When lesions are restricted to either the 
fornix (Sziklas & Petrides, 2002) or the retrosplenial cortex (St-Laurent et al., 2009) no 
impairments on associative learning tasks are observed, but associative learning is severely 
impaired following combined damage to both the fornix and retrosplenial cortex (Dumont et 
al., 2010). Dumont and colleagues (2010) propose that this evidence supports the notion that 
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the ATN and the hippocampus function interdependently in this type of spatial learning, and 
the interaction between these structures relies on both the fornix and the retrosplenial cortex. 
 
These animal lesion studies, have led to models of the ATN involvement in amnesia 
have been proposed. Aggleton and Brown (1999) have suggested that the medial temporal 
lobe and diencephalic structures work in parallel through highlighting the similarity of the 
amnesic syndrome produced by damage each structure. They have proposed a model in 
which they argue that an “extended hippocampal system” comprising the hippocampus, 
fornix, mammillary bodies, and ATN, is essential for the encoding and subsequent recall of 
episodic information (Fig. 3). As a consequence, damage to the component structures of this 
system can result in anterograde amnesia (Aggleton & Brown, 1999). 
 
 
Figure 3. Schematic diagram showing the primary group of interconnections 
underlying spatial memory in the rat (Aggleton & Brown, 1999). 
 
Damage to the extended hippocampal system causes deficits in spatial memory and in 
memory for relational information that characterises memory for autobiographical episodes, 
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but spares recognition based only on familiarity (Aggleton, Vann, Oswald & Good, 2000; 
Mayes et al., 2003; Yonelinas et al., 2002). Aggleton and Brown (1999) have further 
proposed that a reciprocal interaction exists between the hippocampus and the ATN. Support 
for this model comes largely from the disconnection studies explained above, which have 
demonstrated that the ATN and hippocampus are interdependent for some aspects of spatial 
learning. Other support comes from studies that have demonstrated that ATN lesions can 
induce abnormalities in hippocampal activity as measured by the immediate-early gene 
activity (Jenkins et al., 2002a; Jenkins et al., 2002b) and reductions in hippocampal 
acetylcholine levels (Savage et al., 2003). There is also evidence that navigation mechanisms 
that rely on head direction cells are dependent on the projections from the mammillary bodies 
to the ATN and on to the hippocampus (Basset et al., 2005). 
 
Aggleton (2008) has revised the “extended hippocampal system” model by proposing 
that the observed similarity between temporal lobe and diencephalic amnesia may be 
emphasising the fact that both the hippocampus and ATN are connected to a third region, the 
retrosplenial cortex, which possibly functionally links both structures. He asserts that 
dysfunction in the retrosplenial cortex is seen to contribute to both temporal and diencephalic 
amnesia. The retrosplenial cortex has extensive connections with the ATN (Van Groen & 
Wyss, 1995). The AV nuclei especially have prominent connections with the retrosplenial 
cortex, while the AM has more connections with the dorsal anterior cingulate than the 
retrosplenial cortex (Van Groen et al., 1999). Human studies have shown that damage to the 
retrospenial cortex can result in anterograde amnesia (Maguire, 2001; Rudge & Warrington, 
1991). In the animal literature, retrosplenial cortex lesions produce impairments in spatial 
memory (Aggleton & Vann, 2004; Lukoyanov et al., 2005; Vann & Aggleton, 2003), 
although contrary results have also been reported. For example, retrospenial cortex lesions 
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have been noted to produce only mild spatial memory impairments on a T-maze alternation 
task (Pothuizen et al., 2008) and on water maze tasks (Vann & Aggleton, 2004; Van Groen et 
al., 2004). However, it has been suggested that retrosplenial lesions may have a more 
selective effect on spatial working memory, disrupting only some of the strategies the animal 
can use to solve the maze (Pothuizen et al., 2008). 
 
Aggleton (2008) argues that the retroplenial cortex is seen to represent an example of 
“covert pathology” in anterograde amnesia. Covert pathology is used to refer to a brain 
region that appears normal by the standard histological means and yet is functionally 
lesioned. In order to establish whether the retrosplenial cortex does represent covert 
pathology in diencephalic amnesia it is necessary to use a marker for neural function in this 
region, such as immediate-early genes (c-fos). Trans-synaptic activation can stimulate slow 
long-term changes in the post-synaptic neuron that involve the induction of gene expression. 
One of the categories of genes that are responsible for trans-synaptic activation are the 
immediate-early genes. The early activation of c-fos, combined with the fact that they are 
involved in the transcription of other down-stream genes, places c-fos as a potential candidate 
marker for covert pathology (Aggleton, 2008). Examination of c-fos activity after ATN 
lesions has revealed significant losses in early gene activation in the retrosplenial cortex 
(Jenkins et al., 2004). It was also observed that the ATN lesions did not alter the appearance 
of the retrosplenial cortex as determined by standard histological techniques. Interestingly, 
further studies have also shown that the extent of c-fos activity loss increases depending on 
the post-surgical interval, suggesting that retrosplenial cortex dysfunction is enhanced with 
longer survival after ATN lesion surgery (Poirer & Aggleton, 2009). There is also evidence 
that ATN lesions result in a loss of synaptic plasticity in the retrosplenial cortex, as 
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demonstrated through a decrease in long-term depression induction and GABA transmission 
in the region (Garden et al., 2009). 
 
Lesions to the hippocampus also produce similar changes in c-fos activation in the 
retrosplenial cortex (Albasser et al., 2007). This evidence reinforces Aggleton’s (2008) 
suggestion that both temporal lobe and diencephalic amnesia are characterised by hidden 
pathology in the retrosplenial cortex. This hypothesis has interesting implications for human 
neurodegenerative disorders. For example, hypoactivity in the retrosplenial cortex of 
Alzheimer’s disease patients is often one of the first metabolic changes noted on a PET scan 
(Minoshima et al., 1994), and similar changes are often noted in patients with Korsakoff’s 
disease (Nestor et al., 2003). Thus, retrosplenial cortex dysfunction is a common feature in 
both temporal lobe amnesia and diencephalic amnesia and, considering no neuronal loss is 
found in this region, provides a basis for examining potential metabolic-enhancing 
medications such as MB.   
 
 In summary, animals with lesions to the ATN offer an exceptional model with which 
to examine therapeutic interventions for human memory disorders. Animal research has 
provided extensive evidence that the ATN constitutes a part of the extended hippocampal 
system involved in spatial memory processing, and therefore any beneficial effects 
demonstrated from medication/interventions will suggest application as treatment for humans 
with memory disorders where this neural network is damaged. Recent suggestions that 
impaired ATN functioning can negatively affect other brain regions offers interesting 
prospects when researching new medications, where functional gains may be obtained 
through reactivation of regions presenting covert pathology. These findings provide rationale 
for investigating the efficacy of a pharmacological intervention, such as MB, using ATN 
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lesioned rats as a model for diencephalic amnesia, AD, and other human memory disorders. 
The first step, however, is to determine the influence of MB in animals with lesions to the 
extended hippocampal system. 
 
1.7 The Present Study 
 
Current therapeutic intervention studies using the ATN lesion model have focussed 
mainly on environmental enrichment (Loukavenko et al., 2007; Wolff et al., 2008). This 
research has demonstrated that functional recovery to memory can be observed in rats with 
ATN lesions when they are housed in a stimulating environment following surgery. The 
present study is the first to examine a pharmacological intervention for potential recovery of 
function after ATN lesions. To date, the only study that has attempted to explore the 
memory-enhancing effects of MB using a lesion model that replicates the regional pathology 
of AD, diencephalic amnesia or other related memory disorders is that published recently by 
Riha and colleagues (2010). The lesions used in that study were “metabolic” in nature, in that 
the neuronal tissue itself was not damaged and that the memory impairment observed resulted 
from a temporary disruption to CO activity in the retrosplenial cortex. The ATN lesion model 
used in this study produced results in permanent damage to the thalamo-limbic system, which 
can be expected to produce dysfunction in other interconnected neural regions, such as the 
retrosplenial cortex (Garden et al., 2009). Therefore, examining MB using this model 
provides a valid representation of the drug’s potential for treating amnestic disorders in which 
these neural circuits are disrupted. 
 
The present study focussed on a preliminary investigaion of the effects of daily 
administration of MB to ATN-lesioned rats on spatial reference memory in the Morris water 
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maze. Previous research has demonstrated that MB has a positive effect in both normal and 
impaired rats on tasks that test reference memory, such as the baited hole-board maze and the 
water maze (e.g., Callaway et al., 2002, 2004; Deiana et al., 2009; Medina et al., 2010). 
Spatial memory in animals is considered a suitable model of key aspects of episodic memory 
in humans (Dere et al., 2006). The current study therefore employed a standard behavioural 
procedure in the water maze that tests acquisition of allocentric spatial reference memory, 
and this was followed by a probe trial which assesses long-term memory retention. The 
current study is the first to examine the effects of repeat administration of MB using animals 
with permanent lesions that model the regional pathology of human memory disorders. Based 
on prior lesion research, we hypothesised that rats with anterior thalamic lesions would 
display impaired spatial reference memory in the water maze compared to controls, and that 
these impairments would be ameliorated in those lesioned rats treated daily with MB. We 
also predicted that MB would enhance long-term memory retention in ATN-lesioned rats, as 
demonstrated in the probe trial. Older rats (19 to 22 months old) were employed, so the study 
mimics the additional influence of ATN dysfunction in the aging brain. Due to literature 
documenting the general memory-enhancing effects of MB, we also predicted that control 
rats treated with MB would perform better in the water maze than those treated with saline. 
Results from this study may aid the development of MB as new medication for the treatment 
of impaired memory in humans. Due to time contraints, c-fos or CO changes were not 
investigated. Evidence of behavioural improvements after MB administration in ATN rats 
would in any case be a necessary first step. 
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2. MATERIALS AND METHODS 
 
2.1 Subjects 
 
 Subjects were thirty nine male Wistar rats were used, bred in house and weighing 
between 550 and 865g on the day of surgery. They were between 19 and 22 months old at 
time of surgery and, apart from one week for post surgery recovery, were housed 3-4 per cage 
under standard laboratory conditions with a reversed 12 hour light/dark cycle and free access 
to food and water. All testing was undertaken during the dark period. Rats were handled for 2 
weeks prior to surgey and thereafter. The study conformed to the NIH Guide for the Care and 
Use of Laboratory Animals and was approved by the University of Canterbury Animal Ethics 
Committee. In full thirteen rats were excluded from the study, due to insufficient lesions and 
surgery comlpications, leaving the final analysis with twenty six rats. For the first part of the 
experiment rats were divided into 2 groups with final sample sizes of: 12 with ATN lesions 
and 14 Shams. For the second part of the experiment each group was subdivided into 4 
groups: 6 with ATN lesions were treated with MB (MB-ATN), 6 with ATN lesions were 
treated with saline (SA-ATN), 7 Shams were treated with MB (MB-SHAM), and 7 Shams 
were treated with saline (SA-SHAM). 
 
2.2 Drug Administration 
 
Methylene blue (USP-grade; ScienceLab Inc, Houstan, TX, USA) was dissolved in 
saline and administered intraperitoneally (IP) at a dose of 1 mg/kg. This dosage has been 
established from previous research to be most effective in enhancing memory retention in 
normal rats when administered repeatedly (Bruchey & Gonzalez-Lima, 2008). USP-grade 
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MB was used to avoid any impurities, with arsenic measuring a maximum limit of 8ppm, and 
copper and zinc measuring under 0.02%. Rats were administered MB 2 hours after testing to 
avoid immediate symptomatic effects at the time of testing. Blue food colouring was added to 
the saline, and the MB and saline were labelled either solution A or B in order to blind the 
experimenter.  
 
2.3 Apparatus 
 
 The water maze used was a 1.8 metre diameter, 60 cm high white fibreglass pool. The 
pool was situated in a room (5.4 x 4.0 metres) that contained allocentric cues that were both 
2-dimensional (posters attached to the wall) and 3-dimensional (various objects attached to 
the walls including plastic containers and cones, gardening tools, buckets). Other distal cues 
included a computer, a drawn curtain, sink unit, tables and a tall lamp. The water in the maze 
was made opaque by the addition of 1 litre of non-toxic white paint. The pool was virtually 
divided into four equal quadrants with four starting points indentified as north (N), east (E), 
south (S), and west (W). An escape platform (20 cm diameter) was placed 1 cm beneath the 
water surface and kept in a constant position in the pool during each of the acquisition trials. 
The temperature of the water was kept between 20ºC and 23ºC during the testing period, with 
the temperature checked regularly. The swim paths of the rats were tracked using a video 
camera suspended directly above the pool, and all sessions were recorded on videotape. Data 
such as latency, path length and velocity were collected and analysed using the animal 
tracking software Ethovision® XT (Noldus Information Technology, The Netherlands). Due 
to the fact that white Wistar rats were used in this experiment, their heads were stained black 
so that they could be accurately tracked against a white background when using the tracking 
software. 
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2.4 Surgical Procedure 
 
Prior to commencing the final surgeries, 13 pilot surgeries were undertaken. These 
were used to adjust lesion coordinates and NMDA volume in order to produce optimal 
anterior thalamic lesions. Criteria for an optimal lesion were: 1. Minimal Fimbria Fornix and 
Intralaminar Nuclei damage; 2. Lesion is bilateral and does not extend too far anterior or 
posterior; 3. At least 50% of the bilateral AT was damaged. Rats were anaesthetised with 
ketamine (90 mg/kg IP) followed by domitor (1 mg/kg IP). This was supplemented with 
subcutaneous mepivicane (3 mg/kg) during surgery. The anaesthetics were counteracted 
using antisedan (1 mg/kg IP) at the end of surgery. Rats were placed in a stereotaxic frame 
using atraumatic ear bars (Kopf, Tujunga, CA) and the incisor bar was set at -7.5 mm below 
the interaural line to minimise damage to the fornix. Bilateral lesion were directed at the 
anteroventral nucleus (AV) and the anteromedial nucleus (AM). To improve target accuracy, 
one of five anterior-posterior (AP) coordinates was used based on an individual rat’s bregma 
to lamda (B-L) distance (in millimetres). For the AV lesion, the AP coordinates from bregma 
were: -2.55 for B-L = 7.0 or less; -2.60 for B-L = 7.1 to 7.4; -2.65 for B-L = 7.5 to 7.8; -2.70 
for B-L = 7.9 to 8.2; and -2.75 for B-L = 8.2 and over. Two depths were used for the AV 
lesion, with coordinates placed ±1.52 mm lateral from the midline, and -5.68 mm ventral 
(from dura) for the upper site followed by -5.82 mm ventral for the lower site. The AM 
lesions followed an identical scheme except that only one depth was used and lesions were 
placed ±1.20 mm lateral from the midline, -5.95 mm ventral from the dura and the AP was 
0.1 mm more anterior than for the AV site. Either 0.15 µl (for each AV lesion depth) or 0.18 
µl (AM lesion) of 0.12 M N-methyl-d-aspartic acid (NMDA; Sigma, Castle Hills, NSW, 
Australia) in phosphate buffered saline (pH 7.2) was infused over at a rate of 0.03 µl/minute 
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at each site, using an automated Stoelting microinfusion pump and a 1 µl Hamilton syringe 
(Reno, NV, USA). The needle was left in situ for a further 3 min for diffusion at each site and 
retracted slowly. Sham controls received the same surgical procedure, but the needle was 
lowered to 1.50 mm above the lesion coordinates and no NMDA was infused. All rats were 
given at least two weeks to recover following surgery, during which period they were 
monitored daily. 
 
2.5 Behavioural Training 
 
Table 4. Experimental Design. 
Procedure Duration MB or Saline Duration Since 
Previous Test 
Habituation 5 Days  0 
Visible Platform 1 Day  6 Weeks 
1st Reference Memory 
Task 
10 Days  1 Day 
2nd Reference Memory 
Task 
10 Days 1 mg/kg following 
training each day 
5 Days 
Probe Trial 1 Day  7 Days 
 
 
2.5.1 Habituation Phase 
 
Subjects were habituated to the water maze prior to surgery. This included initial 
familiarisation and training to escape on to a visible platform. A visible cue was attached to 
the platform, which was submerged 1 cm below the water surface and curtains were drawn 
around the maze to help the rats focus on the visible escape. The platform was located 15 cm 
perpendicular to a start point and the rat was released at one of four of these points located 
around the maze periphery. Animals were tested with four trials per day on each of the 
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consecutive five days prior to surgery to ensure all rats were swimming comfortably. Each 
habituation trial was terminated once the animal located the visible platform, at which point 
the rat was allowed to remain on the platform for 30 seconds.  During the first few days some 
rats had to be led to the escape platform by the experimenter’s hand. By the fifth day all rats 
were swimming comfortably and were able to reach the escape platform. 
 
2.5.2 Acquisition Phase 
 
2.5.2.1 Visible Platform 
 
Once all rats had recovered from surgery they were given the same procedure as 
conducted preoperatively to ensure that all rats were swimming correctly and could escape 
from the water on to the platform. The platform was placed in a different location to that used 
preoperatively and all rats were tested on a single day. Two rats were excluded from the 
study at this point due to swimming difficulties, possibly as a result of inner ear damage 
during surgery. 
 
2.5.2.2 Part 1: Post-Surgical Spatial Reference Memory Task 
 
 This procedure was used to establish the memory impairment observed in rats with 
ATN lesions compared to the sham rats. The finidings were then used to equate groups to 
receive either MB or saline treatment. During 10 consecutive days, the platform was placed 
in the centre of the north-west quadrant and the curtain surround was drawn back to reveal 
room cues. Each day, the rats were given four 60 second trials in which they were released 
from the four starting points (N, E, S, W) in a random order for each rat. The trial was 
 43 
terminated when the rat reached the hidden platform and had remained there for over 1 
second, at which point it was left on the platform for a further 30 seconds before being 
removed. If the rat did not find the platform within 60 seconds, it was led to it and placed on 
the platform if necessary. All rats were given approximately 4 to 5 minutes between trials. 
The latency was recorded for each trial with a stop watch, and these data used to (a) balance 
spatial memory performace of the control rats that would later receive MB vs saline condions 
(part 2); and (b) to do the same for the ATN rats. Allocation to the two conditions (MB or 
saline treatment) was made by first rank ordering latency (for example, within the controls) 
and randomly allocating one of each successive rank-ordered pairs. 
 
2.5.2.3 Part 2: Post-Surgical Spatial Reference Memory Task and Methylene 
Blue Treatment 
 
Following a five day break, the rats were tested again over 10 consecutive days using 
the same procedure as used during the first reference memory task, except the platform was 
now placed in the south-east quadrant. For part 2, on the day prior to commencing training, 
then 2 hours after each day of training, the rats were given an i.p. injection of either MB or 
saline according their treatment group. Treatment was administered in this fashion as prior 
research has demonstrated that MB has a peak effect on memory using this procedure 
(Bruchey & Gonzalez-Lima, 2008). 
 
2.5.2.4 Probe Trial 
 
Following a 7 day break all rats were tested on one single day to measure the rat’s 
long-term spatial memory for the previous location of the platform (no additional drug was 
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given). During this probe trial the platform were removed from the water maze and the rat 
was allowed to swim for 60 seconds in the pool. The amount of time that the rat spent in the 
previously correct quadrant of the maze and the previous platform location and the frequency 
that the rats reached these areas indicated the strength and precision of their spatial memory. 
 
2.6 Histology 
  
 On completion of behavioural testing, all rats were euthanized using pentobarbitone 
and transcardially perfused with cold saline followed by 4% formalin. The brains were post-
fixed for two days, cytoprotected in 30% sucrose, and every coronal 50-µm section 
throughout the thalamic region was collected using a vibratome for cresyl violet staining of 
cell bodies. Lesion extent was estimated on electronic copies of the Paxinos and Watson 
(1998) atlas. Automated pixel counts of the estimated damage relative to the relevant intact 
brain region were used to generate percent lesion volumes by factoring the pixel areas and the 
distances provided in the atlas. Acceptable lesions were defined as having more than 50% 
bilateral damage to the ATN, but not more than 40% damage to the corresponding adjacent 
thalamic regions. Previous work suggests that ATN lesions with 50% or more damage are 
consistently assocociated with severe memory deficits (Mitchell & Dalrymple-Alford, 2006).  
 
 
2.7 Statistical Analysis 
 
Statistica 10 software was used for statistical analysis. All data were analysed with 
analysis of variance (ANOVA), and p-values with an alpha value of .05 regarded as 
significant. Post-hoc Newman-Keuls tests were used to establish pair-wise comparisons. 
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Priori planned comparisons were used to examine the differences between treatment groups 
following group balancing, and to examine whether the treatment groups performed 
significantly different from chance levels in the probe trial. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 46 
3. RESULTS 
 
3.1 Lesion Evaluation 
 
The largest and smallest acceptable lesions in the two treatment groups are shown in 
Figures 4A & B. Only rats with ATN lesions meeting the Histology criteria (6 MB and 6 
Saline rats) were included in the behavioural analyses (see Table 5). One lesion case was 
rejected because only 12% ATN damage was sustained. In addition, one Sham was excluded 
due to a large hypothalamic tumour. 
A 
     
B               -1.40                                         -1.80                                          -2.12 
     
Figure 4. Lesion Size. Schematic representation of the largest (grey) and smallest (black) 
lesion in the A: MB-treated ATN group and B: Saline-treated ATN group. Numbers indicate 
distance from bregma in millimetres (from Paxinos & Watson (1998)). 
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Table 5. Percentage of bilateral damage (volume) to selected areas for each of the rats in the study.  
 
Abbreviations: AD= anterodorsal nucleus; AM= anteromedial nucleus; ATN = anterior thalamic aggregate comprising the anterodorsal, anteromedial and anteroventral thalamic nuclei; ATN 
median= median percent damage for all included rats; AV= anteroventral nucleus; EE-ATN = rats with anterior thalamic lesions housed in enriched cages; IAM= interanterodorsal nucleus; LT= 
lateral medial thalamic aggregate comprising the intralaminar nuclei (centrolateral, paracentral and rostral central medial nuclei) and lateral mediodorsal thalamic nuclei (lateral and paralamellar 
nuclei); LT median= median percent damage for all included rats; MB-ATN = rats with anterior thalamic lesions treated with methylene blue; MT= posteromedial thalamic aggregate 
comprising the central and medial mediodorsal nuclei and the intermediodorsal nucleus; MT median= median percent damage for all included rats; PT= paratenial nucleus; PVA= anterior 
paraventricular nucleus; PV/PVP= paraventricular nucleus/posterior paraventricular nucleus; Re= reunions nucleus; Rh= rhomboid nucleus; SA-ATN = rats with anterior thalamic lesions 
treated with saline/control. 
  
ATN and 
components     
         
RATS AD AM AV ATN MT LT IAM LD PT PVA PV/PVP Re Rh 
MB-ATN                           
AG2AG 70 43  90  54  0  2  29  1  11  1  0  0  0  
CG11KR 87  70  90  77  0  1  33  5  6  0  0  0  7  
EG15BB 77  57  94  72  0  0  26  2  42  1  0  1 4 
FB17FB 62  39  94  58  0  0  25  0  1  0  0  0  2  
FG18RG 99  63  92  73  10  14  26  3  17  0  0  0  3  
HR24NG 73  40  98  66  0  4  10  7  1  0  0  0  1  
MB-ATN 
Median 75 50 93 69 0 1.5  26 2.5 8.5 0  0  0  2.5  
SA-ATN                           
AB1AB 86 62  87  50 3  9  30 10  8  0  17  0  5  
DB10JR 84  40  92  57  2  10  52  4  9  0  0  0  0  
EB14RR 74  72 92 58 5  13  9  5  7  0  0  0  0 
GG19GG 93  55  94  76  0  0  32  4  19  0  0  0  2  
HB20KB 91 63  98  80  0  6  41  5  20  1  0  0  0  
LR28OG 95  70  93  79  2  7  59  4  20  0  0  0  6  
SA-ATN 
Median 88.5 62.5  93 67 2  8 36.5 4.5 14  0 0  0  1  
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3.2 Part 1: Post-Surgical Spatial Reference Memory Task 
 
As expected, the ATN lesion group displayed poor spatial memory performance, with 
little improvement in the amount of time taken to reach the platform or the path length to the 
platform over the 10 days of training. The Sham group, on the other hand, showed 
improvements in spatial memory over the 10 days of training. Time taken to reach the escape 
platform was analysed using a 2-way repeated measures ANOVA (Lesion by Day), with the 
average of the 4 trials from each training session used as the repeated measure. Assumptions 
of normality and homogeneity were satisfactory, and the alpha was set at .05. A significant 
main Lesion effect was evident (F(9,24) = 6.86; p < 0.015), with poorer performance in the 
ATN group throughout training (Fig. 5A). There was no significant interaction between 
Lesion x Day (F(9,24) < 1.0). ANOVA for the path length to reach the platform also revealed a 
significant Lesion main effect (F(9,24) = 5.70; p < 0.025) (Fig. 5B), with no significant 
interaction between Lesion x Day (F(9,24) < 1.0).   Analysis of the swim speed of the two 
groups revealed that there were no significant differences in velocity (F(9,24) = .541; p > .05) 
(Fig. 5C), indicating that the differences in latency and path length were not due to 
differences in swim speed.  
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Figure 5. Anterior Thalamic Lesions and Spatial Reference Memory Performance in the Morris Water 
Maze. (A) Latency: Mean (± SEM) time (seconds) to reach the escape platform. (B) Path Length: 
Mean (± SEM) distance (centimetres) to reach the escape platform. (C) Velocity: Mean (± SEM) swim 
speed (centimetres per second) during platform searching. ATN = neurotoxic lesion of the anterior 
thalamic nuclei. 
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3.3 Treatment Allocation/ Group Balancing 
 
 Rats were allocated to treatment groups according to their latency performance in Part 
1. They were first rank-ordered into pairs and then rats from each pair were randomly 
allocated to each treatment group. A t-test for path length differences between treatment 
groups in Part 1 revealed that there were no significant differences between the two ATN 
treatment groups (t(10)= -1.07, p > .05) and the two Sham groups (t(12) = -1.24, p > .05). 
The similarity in path length scores in Part 1. indicate that the four treatment groups were 
balanced before commencing MB or saline administration, as path length is generally less 
likely than latency to be influenced by swim speed. 
 
           
Figure 6. Spatial Memory Performance Differences Between Treatment Groups Prior to Drug Administration. 
Path Length: Mean (± SEM) distance (centimetres) to reach the escape platform across the ten days of training. 
MB ATN = Rats with neurotoxic lesions to the anterior thalamic nuclei treated with methylene blue; SA ATN = 
Rats with neurotoxic lesions to the anterior thalamic nuclei treated with saline; MB SHAM = Rats that 
underwent sham/control surgeries treated with methylene blue; MB SHAM = Rats that underwent sham/control 
surgeries treated with saline. 
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3.4 Part 2: Post-Surgical Spatial Reference Memory Task and Methylene Blue 
Treatment 
 
Rats with ATN lesions treated with MB displayed improvements in spatial memoy 
performance across the 10 days of testing, performing at a similar level to the two Sham 
groups. The ATN-lesioned rats treated with saline, on the other hand, showed little 
improvement in spatial memory and performed similary to the ATN group in Part 1 (Fig. 
7A). Sham rats treated with MB did not perform differently from those Sham rats treated with 
saline, although both Sham groups generally performed better than in Part 1. A 3-way 
repeated measures ANOVA (Lesion by Treatment by Day) for the time taken to reach the 
escape platform revealed a significant Lesion main effect (F(9, 24) = 6.66; p < 0.017), 
reflecting a ATN lesion deficit. In addition, there was a significant Lesion by Day interaction 
for latency (F(9, 24) = 2.50; p < 0.05), because the Sham group overall showed more 
improvement in escape time across sessions, while the ATN lesion group overall showed less 
improvement across sessions. The ANOVA revealed that there was no significant main effect 
for treatment (F(9, 24) = 1.17; p > 0.05) and no significant interactions between Lesion x 
Treatment (F(9, 24) = 2.50; p > 0.05) and Lesion x Treatment x Day (F(9, 24) = 1.28; p > 0.05). 
However, Post-hoc Newman-Keuls tests verified that the saline-treated ATN group 
performed significantly worse than the other three groups, whereas the MB-treated ATN 
group did not perform significantly different from the Sham groups. 
 
 Regarding path length (Fig. 7B), a 3-way repeated measures ANOVA (Lesion by 
Treatment by Day) revealed that there was a significant difference between the lesion groups 
(F(9, 24) = 8.40; p < 0.008), and a significant Lesion by Day interaction (F(9, 24) = 1.93; p < 
0.049), mostly because the Sham group swam shorter distances to reach the escape platform 
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across sessions, while the ATN grouped showed less improvement. Furthermore, there was a 
significant 3-way interaction between Lesion x Treatment x Day (F(9, 24) = 1.93; p < 0.049). 
While the MB-treated ATN group and the two Sham groups all improved in performance 
across the sessions, the saline-treated ATN group showed little consistent improvement in 
path length across sessions. There was no significant interaction between Lesion x Treatment 
(F(9, 24) < 1.0). Again, a Post-hoc Newman-Keuls test verified that the MB-treated ATN 
group did not significantly differ from the Sham groups in path length, while the saline-
treated ATN group significantly differed from the three other groups (Fig. 7B). Analysis of 
the swim speed of the four groups in Part 2 revealed no significant differences in velocity 
(F(9, 24) < 1.0) (Fig. 7C), indicating that the differences in latency and path length were not 
due to differences in swim speed. 
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Figure 7. The Effect of Methylene Blue on Spatial Reference Memory Performance in Rats with Anterior 
Thalamic Lesions in the Morris Water Maze. (A) Latency: Mean (± SEM) time (seconds) to reach the escape 
platform across the ten days of training. (B) Path Length: Mean (± SEM) distance (centimetres) to reach the 
escape platform across the ten days of training. (C) Velocity: Mean (± SEM) swim speed (centimetres per 
second) during platform searching. ATN = neurotoxic lesion of the anterior thalamic nuclei; MB = Treatment 
with methylene blue.  
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3.5 Probe Trial 
 
 The graphs for correct quadrant duration, correct zone duration, and zone crossings 
suggest that ATN-lesioned rats treated with saline performed worse than the other three 
groups, whereas the performance of ATN-lesioned rats treated with MB was similar to that of 
the Sham groups (Fig. 8A, B, & C). In addition, the ATN-lesioned rats treated with saline 
also performed at a below chance level (mean second was not significantly different to 15 
seconds in correct quadrant; t(5) = -0.35, p > 0.05), while the other three groups all 
performed above chance level (means were significantly different from 15 seconds in the 
correct quadrant; MB-ATN (t(5) = 2.92, p < 0.05); MB SHAM (t(6) = 2.70, p < 05); SA 
SHAM (t(6) = 2.62, p < 0.05)) (Fig. 8A). However, a 2-way ANOVA (Treatment by Lesion) 
revealed that there were no significant main effects or interactions for either the amount of 
time the rats spent in the correct quadrant, the amount of time the rats spent in the previous 
platform zone, or the frequency that the rats cross into the previous platform zone. The main 
effects for treatment were bordering on significance for both the amount of time spent in the 
correct platform zone (F(9, 24) = 3.24; p < 0.086), and the frequency of correct platform zone 
crossovers (F(9, 24) = 3.55; p < 0.073), while the main treatment effect for amount of time 
spent in the correct quadrant did not approach significance (F(9, 24) < 1.0) Analysis of the 
swim speed of the four groups in this task revealed that there were no significant differences 
in velocity (F(9, 24) = .01; p > 0.05), indicating that the differences in latency were not due to 
differences in swim speed. 
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Figure 8. The Effect of Methylene Blue on Probe Trial Performance in Rats with Anterior Thalamic Lesions in 
the Morris Water Maze. (A) Mean duration (seconds) spent in the previously correct quadrant during the probe 
trial. (B) Mean duration (seconds) spent in the zone where the previous platform was located. (C) Mean 
frequency that the rats crossed over the zone where the previous platform was located. MB ATN = Rats with 
neurotoxic lesions to the anterior thalamic nuclei treated with methylene blue; SA ATN = Rats with neurotoxic 
lesions to the anterior thalamic nuclei treated with saline; MB SHAM = Rats that underwent sham/control 
surgeries treated with methylene blue; MB SHAM = Rats that underwent sham/control surgeries treated with 
saline.  
C 
B 
A 
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5. DISCUSSION 
4.1 General Summary 
 
 The present study aimed to establish whether repeat post-trial administration of MB 
could enhance spatial reference memory in rats with lesions to the anterior thalamus, a region 
implicated in human memory disorders. We established that rats with ATN lesions were 
significantly impaired in the water maze when compared with shams, and that those ATN-
lesioned rats treated with MB showed significantly improved learning compared to those 
treated with saline. While there were no statistically significant differences in the probe trial, 
which examined the long-term memory of the rats, there was a clear trend for the saline-
treated lesioned rats to perform worse than the MB-treated lesioned rats and both of the sham 
groups. A discussion of the findings, strengths and limitations of the study, implications of 
the findings for research and clinical practice, and possible future directions for research are 
described below.  
 
4.2 Anterior Thalamic Lesions and Spatial Memory 
 
As was expected, ATN lesioned rats in the first experiment performed worse than the 
sham group on a measure of spatial reference memory in the water maze. This was 
demonstrated through both a longer duration and a longer swim distance taken to reach the 
escape platform for the ATN lesioned rats compared with the sham rats. These findings are 
consistent with previous research and emphasise the robustness of memory deficits observed 
after ATN lesions. The permanent memory deficits that follow bilateral ATN lesions such as 
those used in the present study, together with similar impairments observed after 
disconnection lesions of the ATN and the hippocampal system, point to the potential 
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importance of the thalamic region as a core part of a system supporting episodic memory 
(Aggleton & Brown, 2006; Byatt & Dalrymple-Alford, 1996; Warburton et al., 2000, 2001). 
The findings support the notion that the ATN serves as a gateway by which information from 
subcortical structures and the hippocampus can be sent to the cortex (Aggleton, 2008). 
Learning to navigate a place in the water maze is also sensitive to damage to both the 
hippocampal system (Morris et al., 1982) and the retrosplenial cortex (Lukoyanov et al., 
2005), and the impairments observed in this study after ATN lesions therefore further 
highlight the anatomical relationships between the three regions and their involvement in the 
episodic memory system.  
 
There is evidence from other studies that while damage to the ATN results in 
impairment in allocentric learning, the ability to navigate based on spatial cues, it does not 
impair performance on egocentric tasks, where the animal learns to use body direction for 
navigation (Sziklas & Petrides, 1999, 2004). Therefore, the impairments demonstrated by the 
ATN rats on the reference memory task may be largely due to an inability of the animals to 
employ an allocentric type strategy in order to solve the maze, and instead a tendency to rely 
on an egocentric strategy to navigate to the platform. This may explain why a minor 
improvement in performance can be observed for the ATN group across the 10 days of 
training, although not at the superior level of the sham group, which would have likely used 
an allocentric strategy to navigate to the escape platform.  Another observation made from 
the latency results is that while the sham rats learnt the position of the escape platform over 
the 10 days of training, they did not reach the reduced latency scores usually found in other 
lesion studies using the reference memory task in the water maze (e.g., Warburton & 
Aggleton, 1999; Wolff et al., 2008). A possible explanation for this may come from the fact 
that the rats used in this study were older than that typically used in ATN lesion studies, and 
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therefore their general learning abilities may be somewhat naturally impaired with the effects 
of aging. It should also be noted that the sham group performed better in terms of both path 
length and latency on the first day of testing, and this may be due to either an improved 
ability to learn the platform position across the first four trials, or that the ATN rats found it 
more difficult to switch from previous platform positions used in the habituation phase of 
testing. 
 
Both clinical and animal research has previously pointed to the fact that structures 
within the thalamus contribute to memory. Evidence from human cases strongly implicate 
disruption of the ATN in the amnesic syndrome associated with both diencephalic amnesia 
(Van der Werf et al., 2000; 2003) and AD (Braak & Braak, 1991b). Animal studies have also 
confirmed that the ATN are implicated in episodic-like memory processes (Aggleton & 
Brown, 1999; Mair et al., 1999; Wolf et al., 2006). The anterior thalamic nuclei have direct 
connections with both the retrosplenial cortex and hippocampal formation (Aggleton, 2008). 
Therefore, the finding that ATN lesioned rats performed worse than the control group on a 
measure of spatial memory should be interpreted as supporting the notion that such deficits 
are due to a disconnection of the ATN from the extended hippocampal system, as supported 
by previous disconnection studies (e.g., Warburton et al., 2000; 2001). Overall, the findings 
of this study therefore further validate ATN-lesioned rats as a model of human memory 
disorders and reinforces the view that the ATN is a critical component of an integrated 
hippocampal-diencephalic system. 
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4.3 The Effect of Methylene Blue on Rats with Anterior Thalamic Lesions 
 
As was consistent with our primary hypothesis, 10 days of continuous 1 mg/kg MB 
treatment resulted in rats with lesions to the anterior thalamus performing better on a measure 
of spatial reference memory than those treated with saline. The MB-treated lesioned rats 
performed equal to the sham groups in their ability to navigate to the escape platform in the 
water maze, while the saline-treated lesioned rats performed worse than the other three 
groups in terms of both path-length and latency. These findings suggest that the application 
of daily low dose MB injections to ATN-lesioned rats can reverse the spatial memory 
impairments induced by the lesion, resulting in learning abilities similar to that of normal, 
aged rats without any observable side effects caused by the drug. This study is therefore the 
first to provide evidence that memory impairments associated with damage to the ATN may 
be ameliorated through a pharmaceutical intervention. Furthermore, this study provides 
evidence that MB may provide beneficial effects for human memory disorders where there 
are disruptions to the thalamo-hippocampal circuit, such as in diencephalic amnesia and AD. 
This indicates that thalamic pathology in such diseases may be a potential target through 
which MB can improve human cognition, as was demonstrated in the Wischik et al. (2008) 
clinical study investigating the application of MB to AD patients. 
 
Given the age and poor acquisition in sham rats, there was no difference in memory 
performance between the MB and saline treated rats in the sham group, suggesting that MB 
had no effect on reference memory in normal rats in the water maze. Previous research, such 
as that conducted by Callaway et al. (2004) and Wrubel et al. (2007b) have demonstrated that 
repeat administration of low dose MB can improve spatial memory in normal rats, and 
therefore we would expect to see a difference in performance between the sham groups. A 
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potential explanation for why no differences were observed may be that both of the sham 
groups performed at an optimal level in the water maze, and no further improvements in 
learning were possible through the application of a memory-enhancing agent such as MB. 
Considering the older age of the rats used in the present study, it is also plausible that normal, 
older rats may not be as responsive to the general memory-enhancing effects of the drug, and 
that such effects are only noticeable in younger rats such as those used in previous MB 
research (e.g., Callaway et al., 2002; Riha et al., 2005; Wrubel et al., 2007a). 
 
Interestingly, the ATN lesioned rats administered MB did not significantly differ from 
those administered saline on the probe trial. While this may suggest that MB does not affect 
long-term memory in ATN lesioned rats, the fact that the graphs display a clear trend for the 
saline-treated ATN rats to perform worse than both the MB-treated ATN rats and the two 
sham groups indicates that MB may have had some effect on the rats’ memory for the 
previous platform location. In addition, the scores of the MB-treated ATN rats was near 
identical to that of the two sham groups, suggesting that the administration of MB resulted in 
normal long term memory for the previous platform position despite anterior thalamic 
damage. Furthermore, the amount of time the saline-treated ATN rats spent in the correct 
quadrant was at a level equivalent to chance, while all three other groups performed at levels 
above chance. There are a number of possible reasons why the differences between the four 
groups on the probe trial did not reach statistical significance. Firstly, there is the possibility 
that MB has only a minimal effect on recall over a longer period, and that its effects may be 
limited to memory consolidation during learning. Additionally, it is possible that that the 
differences were only minimal because the rats were no longer under the influence of the 
drug during the probe trial. The peak of MBs influence on neuronal metabolic activity is 24 
hours following administration (Bruchey & Gonzalez-Lima, 2008), and it is unlikely that any 
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residual effect on metabolism would be present 7 days following the last administration when 
the probe trial was given. Therefore, as no other studies examining the effect of MB on 
spatial memory have employed a probe trial, the findings of the present study may indicate 
that MB only exerts effect on memory during the period where it is metabolically active. 
Nevertheless, the visible differences between the scores of saline administered ATN rats and 
the other three groups imply that further research investigating long-term spatial memory 
needs to be undertaken. 
 
Considering that the ATN lesion model only diplays damage to the anterior thalamus 
while leaving the remaining neural substrate unimpaired, there are a number of possible 
mechanisms through which MB may enhance spatial memory in ATN lesioned rats. Firstly, 
as mentioned previously it has been demonstrated that MB increases neural metabolic 
activity, through increasing CO activity in the brain, and that these effects correspond with 
memory improvements (Callaway et al., 2004; Gonzalez-Lima & Bruchey, 2004; Riha et al., 
2005; Wrubel et al., 2007a). Researchers have found that some mitochondrial genes, 
including transcripts for CO, are up-regulated and over-expressed during memory 
consolidation (Pinter et al., 2005), and increased CO activity results in more oxygen 
consumption and ATP production in the brain (Zhang et al., 2006). With there being no 
damage to either the hippocampus or the retrosplenial cortex in the ATN-lesioned rats, it is 
possible that MB enhances spatial memory performance through increasing CO activity in 
both of these regions. Spatial training in the water maze requires an increase in CO activity in 
both the hippocampus and retrosplenial cortex (Conejo et al., 2010), and there is also 
evidence that ATN lesions results in metabolic impairment in both of the hippocampus 
(Jenkins et al., 2002) and the retrosplenial cortex (Amin et al., 2010; Garden et al., 2009; 
Poirier et al., 2008; van Groen et al., 1993). Therefore, MB may restore the metabolic 
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functioning of these two regions following ATN lesions, resulting in an improved 
functionality of the hippocampal network and, thus, normal spatial memory processing. 
Evidence in support of this notion is provided by the recent study by Riha and colleagues 
(2010), where MB administration resulted in metabolic restoration to the extended 
hippocampal after extensive damage to the retrosplenial cortex. 
 
Another possible way that MB may have improved spatial memory in the ATN-
lesioned rats is through its function as a cholinesterase inhibitor (Pfaffendorf et al., 1997). It 
has been demonstrated that MB can improve reference memory in the water maze in rats 
cholinergically-impaired with scopolamine, and that this memory improvement is superior to 
the commonly used AChEI, rivastigmine (Deiana et al., 2009). Recent research has also 
shown that water maze-tested rats administered with scopolamine show a decrease in CO 
activity in the anterior thalamus, suggesting that the memory deficits induced by scopolamine 
may be due to an impairment in cholinergic function in the ATN and its neural connections 
(Mendez-Lopez et al., 2010). Therefore, the ATN lesions used in the present study may have 
resulted in disruptions to the cholinergic system, and these disruptions may have been 
ameliorated following MB administration, resulting in memory improvement. 
 
The considerations discussed above validate the findings of the present study and 
gives possible explanations as to why MB restores spatial memory in ATN-lesioned rats. 
Other possible mechanisms whereby MB may restore spatial memory are through its action 
as a potent antioxidant, where neuroprotective effects may have been exerted preventing 
further oxidative stress and cell death following the lesions. Also the drugs properties as a 
nitric oxide synthase and guanylate cyclise inhibitor (Deutsch et al., 1996) and influence on 
the glutamatergic system (Vutskits et al., 2008) may also contribute to the drugs positive 
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effects on memory. Although in need of replication with a larger sample size, the current 
findings suggest that repeat low-dose MB administration may prevent the disruptions to the 
thalamo-hippocampal memory system induced by ATN lesions and supports the ongoing 
research investigating MB as a potential candidate for the treatment of human 
neurodegenerative disorders. 
 
4.4 Strengths 
 
Along with demonstrating that MB has a positive effect on memory in rats with 
lesions to the anterior thalamus, this is also the first study to explore a number of other 
research avenues. To begin with, to our knowledge this is the first time an ATN-induced 
memory deficit has been demonstrated in older rats. The standard rat age at time of surgery 
used in research using the ATN lesion model is between 3-6 months old (e.g., Poirier & 
Aggleton, 2009; van Groen et al., 2002; Warburton et al., 1997; 2001), with the oldest rats 
used in any study being 10 months old (Wolff et al., 2008). Similarly, this study presents the 
first time that the memory-enhancing effects of MB has been examined using older rats. The 
rats used in the present study, on the other hand, were all aged between 19-22 months old at 
the time of surgery. Considering that the neurodegenerative disorders, such as diencephalic 
amnesia and AD, most commonly occur in older patients, it can be argued that the rats used 
in the present study offer a more valid model of human memory disorders present in the 
geriatric population. Additionally, this study demonstrates that lesion induced differences in 
memory are present in older rats despite potential existing natural memory impairments that 
may be present due to the rat’s age. 
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Previous research, especially that focussing on MB as a therapeutic agent for 
neurodegenerative disorders, has used either a single dose (e.g., Callaway et al., 2002; Riha et 
al., 2010) or a maximum of 5 days continuous treatment (Callaway et al., 2004; Wrubel et al., 
2007b). However, the present study used a treatment regime of 10 days continuous 
administration of 1 mg/kg MB, with no apparent side effects being noted by the researcher. 
This is highly relevant when the findings are considered in the context of human treatment, 
where patients would potentially be treated with MB over a prolonged period. Current human 
AD trials have found beneficial effects following 6 months of continuous oral treatment 
(Wischik et al., 2008). Therefore, future animal and human research should aim to use longer 
administration periods when investigating AD as a potential treatment for memory disorders. 
 
The present study demonstrates that MB is effective in improving spatial memory 
using a reference memory procedure of this sort in the water maze. Studies examining the 
memory-enhancing effects of MB in normal rats have typically used the baited holeboard 
maze, where odour cues can confound results (e.g., Callaway et al.,2002; Wrubel et al., 
2007b). An exception is the study examining MB using rats administered scopolamine by 
Deiana and colleagues (2009), where a variation of the reference memory procedure was used 
in the water maze. However, this study did not examine memory improvement over time, and 
instead examined short-term memory through employing a probe trial after 6 consecutive 
training trials. The present study can therefore be considered the first study to examine 
methylene blue using a reference memory training protocol over a extended period. 
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4.5 Limitations 
 
The present study also has a number of limitations worth acknowledging that should 
be addressed in future research. Firstly, the sample size used was smaller than intended which 
may affect the validity of the findings. Unfortunately, due to the nature of the lesion surgery 
and the advanced age of the rats, during histology two rat were found to have large brain 
tumours that impinged on the thalamic region and others had swimming difficulties. 
Therefore, these rats were not included in the study. It is possible that if the sample sizes 
were increased we may have seen even further discrepancies between the treatment groups. 
Therefore, the current study could be viewed as a pilot study for a similarly designed study 
with a larger sample size.  
 
In addition, while the advanced age of the rats can be considered a strength of the 
study in terms of increasing the lesioned rat’s validity as a model of AD, it is also possible 
that performance in the water maze may have been impaired due to the older age of the rats. 
This is supported by literature that has demonstrated that aged rats can vary in water maze 
performance, where some show clear spatial reference memory deficits while others are not 
impaired and show cognitive capacities similar to those of younger rats (Gallagher & Nicolle, 
1993). It has been demonstrated that this variability may be due to impaired hippocampal 
neurogenesis in some older rats (Drapeau et al., 2003). While the MB vs. Saline groups 
appeared to be balanced in terms of performance scores prior to drug administration, there 
were some minor differences, with the rats receiving MB generally performing slightly better 
in the first testing segment. Therefore, the older rats used in the present study may have 
varied in pre-existing hippocampal impairment prior to surgery, and thus, some may have 
shown more spatial memory impairment than others during testing. 
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Another limitation to the current study is that only one dose level of MB was 
investigated. A number of recent studies have examined the effects of a range of MB doses 
(0.5-4 mg/kg) on spatial memory in rats, with general findings that higher doses of up to 4 
mg/kg result in greater improvements in spatial memory (Deiana et al., 2009), while doses 
exceeding 4 mg/kg have a negative impact on spatial memory and can produce anxiogenic 
effects (Bruchey & Gonzalez-Lima, 2008). This demonstrates the hormetic dose-response of 
MB, where effects are diminshed with higher doses until they reach baseline (Bruchey & 
Gonzalez-Lima, 2008), and such dose responses are of great importance when investigating 
optimal treatment dosage. The present study would have benefited from including a range of 
MB doses to the treatment regime as it would be interesting to discover the differing effects 
that smaller and larger doses of MB may have on spatial memory in ATN-lesioned rats, and 
such findings would contribute greatly to the development of MB as a human 
pharmacological intervention. 
 
Although the present study demonstrated beneficial effects on memory of MB in 
ATN-lesioned rats following MB administration, there is no definite way to infer from the 
results the potential mechanism through which MB exerted its effects. Previous research has 
spefically examined  CO levels in conjunction with memory-enhancing effects of MB, and 
there is evidence to suggest that increased CO levels is the mechanism through which MB 
exerts its beneficial effects (Callaway et al., 2004; Gonazalez Lima & Bruchey, 2004; Riha et 
al., 2005; Wrubel et al., 2007b). As stated above, there are various ways through which MB 
could have increased CO levels in the ATN lesioned rats which may have contributed to the 
observed memory improvement, and therefore, it is important that future research looks at 
CO levels in ATN-lesioned rats and what changes occur after MB administration. 
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4.6 Implications 
 
To our knowledge, no attempt has been made prior to the current study, apart from 
research by our lab using the drug cerebrolysin (in prep), to use a pharmacological 
intervention to ameliorate the behavioural deficits observed after lesions to the anterior 
thalamus, which is strongly implicated in contributing to the severity of the amnestic disorder 
in both AD and diencephalic amnesia. The current study therefore demonstrates that MB has 
beneficial effects for memory following ATN lesions, and these findings have a number of 
implications relating to research for human memory disorders. As stated previously, there are 
currently human clinical trials that are investigating the efficacy of MB as a treatment for 
human AD patients, and findings so far have been impressive (Wischik et al., 2008). These 
trials have focussed on the action of MB on neurofibrillary tangles, with the authors 
suggesting that MB’s tau-dissolving properties are largely responsible for the improved 
memory performance in AD patients administered the drug. However, research following the 
publication of the AD trials has demonstrated inconsistent effects of MB on NFTs, and also 
shown that MB has potential action on a number of other pathologies associated with AD. 
The current study therefore adds to this research by suggesting that MB may ameliorate 
memory disturbances associated with damage to the anterior thalamus, and that this action 
may also contribute to the beneficial effects observed in the human clinical trials. 
 
Pharmaceutical grade (USP) MB is an FDA approved drug with powerful antioxidant 
activity that is currently most commonly prescribed for metheglobinemia (Bradberry, 2003). 
While chemical grade MB is an industrial dye that may contain contaminants with potential 
toxicity (Auerbach et al., 2010), purified pharmaceutical grade MB used at low doses has no 
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toxic effect in humans (Bradberry, 2003). The ability of MB to permeate the blood-brain 
barrier and its unique pharmokinetic properties make it attractive as a potential therapeutic 
agent. MB presents with a pharmacological profile that differs from the commonly prescribed 
cholinesterase inhibitors and may provide a novel approach for the treatment of cognitive 
impairments in neurodegenerative diseases. Due to its metabolic-enhancing and 
neuroprotective effects, MB could have disease-modifying effects for such diseases without 
the side effects and high costs associated with currently prescribed pharmaceutical 
treatments. 
 
4.7 Future directions 
 
There are a number of ways in which the current study can be built upon in future 
research. To begin with, the effects of MB should also be examined in young rats with ATN 
lesions. While using older rats in the present study may have resulted in a rodent model that 
is more representative of human neurodegenerative diseases, their use may also have had a 
negative impact on performance in the water maze. In addition, the majority of research on 
the behavioural effects of thalamic lesions has used young rats and it would be interesting to 
see if even greater improvement in memory are observed in rats that are not already 
cognitively impaired to varying extents due to old age. Furthermore, while the current study 
assessed MB using a reference memory procedure, future research should trial MB in ATN-
lesioned rats using a variety of memory procedures, such as working memory and fear 
conditioning. A working memory procedure would be particularly useful in that it would 
allow the experimentors to assess various doses of MB using the same subjects through 
administering a different dose for a different platform position following a sufficient wash-
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out period. A variety of different doses should be examined in future research as this is 
valuable information that can be applied to clinical research. 
 
The only other study to date that has demonstrated recovery of function in ATN-
lesioned rats following a therapeutic intervention is that by Loukavenko et al. (2007), which 
showed that rats housed in a stimulating environment or given cerebrolysin (in prep) 
following surgery showed improved memory performance compared with those lesioned rats 
housed in a standard environment. Therefore, ATN-lesioned rats exposed to a combination of 
both MB and an enriched environment may show further recovery of function in terms of 
memory impairment. Pharmaceutical combination therapies could also be investigated, such 
as combining currently used memory-enhancing medications with MB. The recent study by 
Deiana et al. (2009) has provided evidence that the combination of the AChEI rivastigmine 
with MB resulted in further improvements in spatial memory in scopolamine-impaired rats 
when compared to those treated with either drug alone. Therefore, such improved 
performance from combined therapy may also be observed in rats with ATN lesions, with 
findings being particularly useful in the development of a new pharmaceutical interventions. 
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